Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 26;15(1):191.
doi: 10.1186/s13018-020-01709-3.

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Tomoko Tetsunaga  1   2 , Tomonori Tetsunaga  3 , Keiichiro Nishida  1 , Haruo Misawa  1 , Tomoyuki Takigawa  1 , Kentaro Yamane  1 , Hironori Tsuji  1 , Yoshitaka Takei  2 , Toshifumi Ozaki  1
Affiliations

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Tomoko Tetsunaga et al. J Orthop Surg Res. .

Abstract

Background: Mirogabalin, which is approved for the treatment of peripheral neuropathic pain in Japan, is a ligand for the α2δ subunit of voltage-gated calcium channels. Both pregabalin and mirogabalin act as nonselective ligands at the α2δ-1 and α2δ-2 subunits. Mirogabalin has a unique binding profile and long duration of action. Pregabalin has been reported to produce intolerable adverse effects in some patients. This study investigated outcomes associated with mirogabalin administration in patients with peripheral neuropathic pain who ceased treatment with pregabalin.

Methods: We retrospectively assessed peripheral neuropathic pain using the neuropathic pain screening questionnaire (NeP score) in 187 patients (58 men, 129 women) who were treated with mirogabalin. All patients had switched from pregabalin to mirogabalin due to lack of efficacy or adverse events. Differences in the treatment course (i.e., numeric rating scale (NRS) scores) were compared using one-way analysis of variance with Bonferroni post hoc tests.

Results: The mean age of the patients was 72.3 years (range, 30-94 years), and the mean duration of disease was 37 months (range, 3-252 months). After treatment with mirogabalin for 1 week, NRS scores significantly decreased compared with baseline and continued to decrease over time. After 8 weeks, NRS scores improved by ≥ 30% from baseline in 113 patients (69.3%). Twenty-four patients (12.8%) stopped mirogabalin treatment due to adverse events. Somnolence (26.7%), dizziness (12.3%), edema (5.9%), and weight gain (0.5%) were noted as adverse events of mirogabalin.

Conclusions: The results of this investigation indicate that mirogabalin is safe and effective for reducing peripheral neuropathic pain.

Keywords: Adverse event; Mirogabalin; Peripheral neuropathic pain; Pregabalin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Scores on the numeric rating scale (NRS) were significantly reduced after 8 weeks of treatment with mirogabalin. Data are expressed as the mean ± standard deviation. *p < 0.05
Fig. 2
Fig. 2
The magnitude of numeric rating scale (NRS) improvement after 8 weeks of treatment with mirogabalin. No significant differences were observed in the magnitude of NRS improvement in patients taking maximum doses of 5 mg/day (n = 47), 10 mg/day (n = 89), 20 mg/day (n = 32), and 30 mg/day (n = 19). Data are expressed as the mean ± standard deviation. N.S., not significant
See this image and copyright information in PMC

References

    1. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–2205. doi: 10.1016/j.pain.2011.06.017. - DOI - PubMed
    1. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95–112. doi: 10.2165/00019053-200927020-00002. - DOI - PubMed
    1. Baron R, Binder A. [How neuropathic is sciatica? The mixed pain concept]. Orthopade. 2004;33:568-75. doi: 10.1007/s00132-004-0645-0 [doi]. - PubMed
    1. Freynhagen R, Baron R. Gockel U. Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911–1920. doi: 10.1185/030079906x132488. - DOI - PubMed
    1. Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev. 2018;70:315–347. doi: 10.1124/pr.117.014399. - DOI - PubMed

LinkOut - more resources